𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tumor scintigraphy with131I anti CEA monoclonal antibodies andF(ab′)2in colorectal cancer

✍ Scribed by E. Henze; R. Kübel; J. Waitzinger; M. Büchler; W. E. Adam; H. G. Beger

Book ID
104706219
Publisher
Springer
Year
1987
Tongue
English
Weight
627 KB
Volume
13
Category
Article
ISSN
0340-6997

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase-I/II radio-immunotherapy study wit
Phase-I/II radio-immunotherapy study with iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab′)2 in patients with non-resectable liver metastases from colorectal cancer
✍ Marc Ychou; André Pelegrin; Patrick Faurous; Bruno Robert; Jean-Claude Saccavini 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 85 KB 👁 2 views

Experimental studies in nude mice with human coloncarcinoma grafts demonstrated the therapeutic efficiency of F(abЈ) 2 fragments to carcinoembryonic antigen (CEA) labeled with a high dose of 131 Iodine. A phase I/II study was designed to determine the maximum tolerated dose of 131 I-labeled F(abЈ) 2

Phase I/II trial of combined 131I anti-C
Phase I/II trial of combined 131I anti-CEA monoclonal antibody and hyperthermia in patients with advanced colorectal adenocarcinoma
✍ Bharat B. Mittal; Michael A. Zimmer; Vythialingam Sathiaseelan; Al B. Benson III 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 939 KB

BACKGROUND. This pilot project was undertaken to evaluate the toxicity of and tumor response to combined 13'1 anti-carcinoembryonic antigen monoclonal antibody ('"I anti-CEA RMoAb) and hyperthermia in patients with metastatic colorectal adenocarcinoma.

Phase I/II trial of 131I-MN-14 F(ab)2 an
Phase I/II trial of 131I-MN-14 F(ab)2 anti–carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma
✍ Malik E. Juweid; George Hajjar; Lawrence C. Swayne; Robert M. Sharkey; Samer Sul 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 464 KB 👁 1 views

## BACKGROUND. Monoclonal antibodies (MAbs) against carcinoembryonic antigen (CEA) have been recognized as targeting agents for medullary thyroid carcinoma (MTC). This Phase I/II study was initiated to determine the safety, maximum tolerated dose (MTD), and therapeutic potential of 131 I-MN-14 F(ab